Unmet needs in patients with moderate-to-severe plaque psoriasis treated with methotrexate in real world practice: FirST study
Background Methotrexate (MTX) is frequently used in the treatment of moderate-to-severe psoriasis, however, there is limited data on health-related quality-of-life (HRQoL), psoriasis clinical outcomes and hepatic fibrosis in MTX-treated patients in routine clinical practice. Objectives To investigat...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-04-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2020.1801977 |
| _version_ | 1797683553463435264 |
|---|---|
| author | Raquel Rivera E. Vilarrasa M. Ribera E. Roe T. Kueder-Pajares A. I. Zayas L. Martínez-Molina J. Mataix Díaz I. M. Rodríguez-Nevado T. Usero-Bárcena D. de la Mano C. García-Donoso A. Olveira G. Guinea V. Martín-Vázquez M. Ferran |
| author_facet | Raquel Rivera E. Vilarrasa M. Ribera E. Roe T. Kueder-Pajares A. I. Zayas L. Martínez-Molina J. Mataix Díaz I. M. Rodríguez-Nevado T. Usero-Bárcena D. de la Mano C. García-Donoso A. Olveira G. Guinea V. Martín-Vázquez M. Ferran |
| author_sort | Raquel Rivera |
| collection | DOAJ |
| description | Background Methotrexate (MTX) is frequently used in the treatment of moderate-to-severe psoriasis, however, there is limited data on health-related quality-of-life (HRQoL), psoriasis clinical outcomes and hepatic fibrosis in MTX-treated patients in routine clinical practice. Objectives To investigate the impact of moderate-to-severe psoriasis in MTX-treated patients in Spain regarding to HRQoL, psoriasis clinical data and risk of hepatic fibrosis. Methods Observational, non-interventional, cross-sectional, retrospective, multicentre study, performed in Spain in moderate-to-severe plaque psoriasis patients treated with MTX > 16 weeks prior to inclusion. Results Despite ongoing treatment, 17.1% of 457 evaluable patients reported moderate-to-extreme impact on HRQoL (DLQI > 5); 21.4% BSA > 5 and 35.2% moderate-to-severe pruritus (VAS ≥ 4). Persistent severe psoriasis (PASI ≥ 10 and/or DLQI ≥ 10) was observed in 10.7%. Hepatic steatosis was identified in 64.1% of patients (HSI ≥ 36) and 37.2% of the patients were at-risk of advanced fibrosis which was associated to the MTX treatment duration. Conclusions The study identified unmet needs in moderate-to-severe plaque psoriasis patients treated with MTX, revealing a significant proportion of sub-optimally controlled patients in terms of HRQoL and different domains of the disease. This study also found patients at-risk of advanced fibrosis, with evidence suggesting a correlation between longer exposures to MTX and higher risk of advanced fibrosis. |
| first_indexed | 2024-03-12T00:15:53Z |
| format | Article |
| id | doaj.art-4af7528978a741978b9bf964850da313 |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:15:53Z |
| publishDate | 2022-04-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-4af7528978a741978b9bf964850da3132023-09-15T14:28:49ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532022-04-013331329133810.1080/09546634.2020.18019771801977Unmet needs in patients with moderate-to-severe plaque psoriasis treated with methotrexate in real world practice: FirST studyRaquel Rivera0E. Vilarrasa1M. Ribera2E. Roe3T. Kueder-Pajares4A. I. Zayas5L. Martínez-Molina6J. Mataix Díaz7I. M. Rodríguez-Nevado8T. Usero-Bárcena9D. de la Mano10C. García-Donoso11A. Olveira12G. Guinea13V. Martín-Vázquez14M. Ferran15Department of Dermatology, Hospital Universitario Doce de OctubreDepartment of Medicine, Universitat Autònoma de BarcelonaDepartment of Dermatology, Hospital Universitari Parc TaulíDepartment of Medicine, Universitat Autònoma de BarcelonaDepartment of Dermatology, Hospital Universitario de FuenlabradaDepartment of Dermatology, Doctor Peset Universitary HospitalDepartment of Dermatology, Hospital de ViladecansDepartment of Dermatology, Marina Baixa HospitalDepartment of Dermatology, Hospital Infanta Cristina, Complejo Hospitalario Universitario de BadajozDepartment of Dermatology, Hospital Universitario Lucus AugustiDepartment of Dermatology, Hospital San Agustín, Avilés, Principado de AsturiasDepartment of Dermatology, Hospital Universitario Doce de OctubreDepartment of Gastroenterology, Hospital Universitario La PazMedical Department, Novartis FarmacéuticaMedical Department, Novartis FarmacéuticaDepartment of Dermatology, Hospital del MarBackground Methotrexate (MTX) is frequently used in the treatment of moderate-to-severe psoriasis, however, there is limited data on health-related quality-of-life (HRQoL), psoriasis clinical outcomes and hepatic fibrosis in MTX-treated patients in routine clinical practice. Objectives To investigate the impact of moderate-to-severe psoriasis in MTX-treated patients in Spain regarding to HRQoL, psoriasis clinical data and risk of hepatic fibrosis. Methods Observational, non-interventional, cross-sectional, retrospective, multicentre study, performed in Spain in moderate-to-severe plaque psoriasis patients treated with MTX > 16 weeks prior to inclusion. Results Despite ongoing treatment, 17.1% of 457 evaluable patients reported moderate-to-extreme impact on HRQoL (DLQI > 5); 21.4% BSA > 5 and 35.2% moderate-to-severe pruritus (VAS ≥ 4). Persistent severe psoriasis (PASI ≥ 10 and/or DLQI ≥ 10) was observed in 10.7%. Hepatic steatosis was identified in 64.1% of patients (HSI ≥ 36) and 37.2% of the patients were at-risk of advanced fibrosis which was associated to the MTX treatment duration. Conclusions The study identified unmet needs in moderate-to-severe plaque psoriasis patients treated with MTX, revealing a significant proportion of sub-optimally controlled patients in terms of HRQoL and different domains of the disease. This study also found patients at-risk of advanced fibrosis, with evidence suggesting a correlation between longer exposures to MTX and higher risk of advanced fibrosis.http://dx.doi.org/10.1080/09546634.2020.1801977health-related quality of lifehepatic fibrosishepatic steatosismethotrexatepsoriasisspain |
| spellingShingle | Raquel Rivera E. Vilarrasa M. Ribera E. Roe T. Kueder-Pajares A. I. Zayas L. Martínez-Molina J. Mataix Díaz I. M. Rodríguez-Nevado T. Usero-Bárcena D. de la Mano C. García-Donoso A. Olveira G. Guinea V. Martín-Vázquez M. Ferran Unmet needs in patients with moderate-to-severe plaque psoriasis treated with methotrexate in real world practice: FirST study Journal of Dermatological Treatment health-related quality of life hepatic fibrosis hepatic steatosis methotrexate psoriasis spain |
| title | Unmet needs in patients with moderate-to-severe plaque psoriasis treated with methotrexate in real world practice: FirST study |
| title_full | Unmet needs in patients with moderate-to-severe plaque psoriasis treated with methotrexate in real world practice: FirST study |
| title_fullStr | Unmet needs in patients with moderate-to-severe plaque psoriasis treated with methotrexate in real world practice: FirST study |
| title_full_unstemmed | Unmet needs in patients with moderate-to-severe plaque psoriasis treated with methotrexate in real world practice: FirST study |
| title_short | Unmet needs in patients with moderate-to-severe plaque psoriasis treated with methotrexate in real world practice: FirST study |
| title_sort | unmet needs in patients with moderate to severe plaque psoriasis treated with methotrexate in real world practice first study |
| topic | health-related quality of life hepatic fibrosis hepatic steatosis methotrexate psoriasis spain |
| url | http://dx.doi.org/10.1080/09546634.2020.1801977 |
| work_keys_str_mv | AT raquelrivera unmetneedsinpatientswithmoderatetosevereplaquepsoriasistreatedwithmethotrexateinrealworldpracticefirststudy AT evilarrasa unmetneedsinpatientswithmoderatetosevereplaquepsoriasistreatedwithmethotrexateinrealworldpracticefirststudy AT mribera unmetneedsinpatientswithmoderatetosevereplaquepsoriasistreatedwithmethotrexateinrealworldpracticefirststudy AT eroe unmetneedsinpatientswithmoderatetosevereplaquepsoriasistreatedwithmethotrexateinrealworldpracticefirststudy AT tkuederpajares unmetneedsinpatientswithmoderatetosevereplaquepsoriasistreatedwithmethotrexateinrealworldpracticefirststudy AT aizayas unmetneedsinpatientswithmoderatetosevereplaquepsoriasistreatedwithmethotrexateinrealworldpracticefirststudy AT lmartinezmolina unmetneedsinpatientswithmoderatetosevereplaquepsoriasistreatedwithmethotrexateinrealworldpracticefirststudy AT jmataixdiaz unmetneedsinpatientswithmoderatetosevereplaquepsoriasistreatedwithmethotrexateinrealworldpracticefirststudy AT imrodrigueznevado unmetneedsinpatientswithmoderatetosevereplaquepsoriasistreatedwithmethotrexateinrealworldpracticefirststudy AT tuserobarcena unmetneedsinpatientswithmoderatetosevereplaquepsoriasistreatedwithmethotrexateinrealworldpracticefirststudy AT ddelamano unmetneedsinpatientswithmoderatetosevereplaquepsoriasistreatedwithmethotrexateinrealworldpracticefirststudy AT cgarciadonoso unmetneedsinpatientswithmoderatetosevereplaquepsoriasistreatedwithmethotrexateinrealworldpracticefirststudy AT aolveira unmetneedsinpatientswithmoderatetosevereplaquepsoriasistreatedwithmethotrexateinrealworldpracticefirststudy AT gguinea unmetneedsinpatientswithmoderatetosevereplaquepsoriasistreatedwithmethotrexateinrealworldpracticefirststudy AT vmartinvazquez unmetneedsinpatientswithmoderatetosevereplaquepsoriasistreatedwithmethotrexateinrealworldpracticefirststudy AT mferran unmetneedsinpatientswithmoderatetosevereplaquepsoriasistreatedwithmethotrexateinrealworldpracticefirststudy |